- Conditions
- Heart, Heart Failure, Ejection Fraction, Left Ventricular Ejection Fraction, Left Ventricular Ejection Fraction Less Then or Equal to 50percent
- Interventions
- PLAX EF Manual vs. Automatic Measurement
- Device
- Lead sponsor
- EchoNous Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Hollywood, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 175
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Modeling of Recruitment Curves
- Interventions
- Algorithm: Uniform Sampling, Algorithm: hbMEP-adaptive algorithm (version 1), Algorithm: hbMEP-adaptive algorithm (version 2), ML-PEST, MagPro X100 Transcranial Magnetic Stimulation, Digitimer DS8R Transcutaneous Electrical stimulation
- Other · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Colon Cancer, Lung Cancer, Neuroblastoma, Testicular Cancer
- Interventions
- Focus Group Sessions
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Interventions
- Transcutaneous auricular vagus nerve stimulation, Sham device
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- New Hyde Park, New York • Philadelphia, Pennsylvania
- Conditions
- Burns, Insulin Resistance
- Interventions
- fenofibrate
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Attention Deficit and Disruptive Behavior Disorders
- Interventions
- Doctor-office collaborative care (DOCC) management, Treatment as usual (TAU)
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 858 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2013
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cetuximab, molecular diagnostic method, immunologic technique, laboratory biomarker analysis
- Biological · Genetic · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
- Interventions
- Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).
- Procedure · Diagnostic Test · Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Male Erectile Disorder, Prostate Cancer, Sexual Dysfunction
- Interventions
- Sexual Health Inventory for Men (SHIM) questionnaire administration, management of therapy complications, Daily vacuum therapy
- Other · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Up to 70 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lung Cancer
- Interventions
- Veran System
- Device
- Lead sponsor
- Veran Medical Technologies
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Baltimore, Maryland + 6 more
- Conditions
- Hypogonadism
- Interventions
- Oral Testosterone Undecanoate
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Alzheimer Disease
- Interventions
- LX1001
- Biological
- Lead sponsor
- Lexeo Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Durham, North Carolina
- Conditions
- Allergic Conjunctivitis
- Interventions
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Voice of Sleep "MamaBee" training modules (Fairy Tales)
- Device
- Lead sponsor
- Pisareva Citadel Group LLC
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- NewYork, New York
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- Methodology
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Mental Illness
- Interventions
- Vocational Empowerment Photovoice (VEP)
- Behavioral
- Lead sponsor
- Boston University Charles River Campus
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Dorchester, Massachusetts • Brentwood, New York
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 16 Years to 85 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 8
- States / cities
- San Diego, California • San Francisco, California • Tampa, Florida + 5 more
- Conditions
- Healthy Subjects
- Interventions
- INTERCEPT Blood System for Platelets with LED Illuminator
- Device
- Lead sponsor
- Cerus Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Norfolk, Virginia • Seattle, Washington
- Conditions
- Healthy
- Interventions
- PF-04995274
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Sickle Cell Disease
- Interventions
- Quality Improvement
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 715 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Bipolar Disorder, Involutional Depression, Mood Disorder
- Interventions
- Ethyl Eicosapentaenoic Acid, OmegaBrite
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Lower Back Pain
- Interventions
- Mechanical Diagnosis and Therapy, Manual Therapy
- Procedure
- Lead sponsor
- Canandaigua VA Medical Center
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Stroke, Cognitive Change, Neurological Injury, Cognitive Impairment, Activity, Motor
- Interventions
- Ageless Grace
- Behavioral
- Lead sponsor
- Saint Joseph's University, Philadelphia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma Multiforme
- Interventions
- ACP-196
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 2 more